Aptimmune Biologics, a Champaign, IL-based mucosal vaccine company developing novel swine vaccines for PRRSV and influenza virus, raised $2.75m in funding.
Backers included Arsenal Capital Management, Fox Ventures and a group of Midwest angel investors.
The company intends to use the funds to accelerate its mucosal vaccine candidates through development and product registration.
Led by Aaron Gilbertie, CEO, Aptimmune will create new swine vaccines based on advanced mucosal technology.
Dr. Federico Zuckermann, founder and Chief Scientific Officer, is a swine immunologist, professor at the University of Illinois, and inventor of patented vaccine technologies commercialized by the company.